Ann: Notice of General Meeting/Proxy Form, page-8

I hope for your sake dsorg that is the case.

Recursion (RXRX) had a huge night where it was up over 21% continuing its recent strong performance and now has a market cap of over US$3.2 billion. Not saying that Algorae is like Recursion but like Recursion there are long and short term ways in which it can generate value.

The AI platform will generate fixed dose combination drug targets that Algorae can either develop themselves in clinical trial programs or alternatively those drug targets could be out-licensed in partnership arrangements.

For instance, Bayer has partnered with RXRX to use RecursionOS in the field of Fibrosis in a deal including US$30 million upfront and a US$50 million equity investment, up to US$1.2 billion in milestone payments for drug targets that develop into drug products with royalties also applying in the event of achieving FDA marketing approval.

The unique and exclusive relationship between the UNSW and Algorae truly is exciting. From my research UNSW hands down has not only the best AI platform in this field in Australia but also the most qualified people to go with it.